Trial Profile
A Phase 1 Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 13 Oct 2022
Price :
$35
*
At a glance
- Drugs Etrumadenant (Primary) ; Zimberelimab (Primary)
- Indications Adenocarcinoma; Advanced breast cancer; Bladder cancer; Colorectal cancer; Endometrial cancer; Gastric cancer; Head and neck cancer; Malignant melanoma; Merkel cell carcinoma; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Prostate cancer; Renal cell carcinoma; Squamous cell cancer
- Focus Adverse reactions
- Sponsors Arcus Biosciences
- 21 Dec 2021 Time-frame for the primary end-point "Percentage of participants with Adverse Events" is increased from 1 year to 3 years.
- 07 Oct 2021 Status changed from active, no longer recruiting to completed.
- 25 Aug 2021 Planned End Date changed from 30 Sep 2021 to 31 Oct 2021.